USANA
February 6, 2024
SALT LAKE CITY, February 6, 2024 --
USANA Health Sciences reported fourth-quarter 2023 net sales of 221 million dollars, down 3 percent from 228 million dollars a year earlier, with diluted earnings per share of 0.87 dollars, up 32 percent from 0.66 dollars. Active customers ended the quarter at 483,000, down 1 percent year over year and up 4 percent sequentially.
Full-year 2023 net sales were 921 million dollars, down 8 percent from 999 million dollars, and diluted EPS was 3.30 dollars compared with 3.59 dollars. Chief Executive Jim Brown said a global incentive offering helped Greater China finish stronger and that the company commenced operations in India, its 25th market, near the end of the fourth quarter.
USANA introduced 2024 guidance for net sales of 850 million to 920 million dollars and diluted EPS of 2.40 to 3.00 dollars, citing challenging economic conditions and about 25 million dollars of first-quarter 2023 sales that are not expected to recur. The company ended the year with 330 million dollars in cash.